Navigation Links
Cardica to Announce Fiscal 2013 Fourth Quarter and Full Year Financial Results On Monday, August 5, 2013

REDWOOD CITY, Calif., July 22, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that it will release financial results for its fiscal fourth quarter and full year ended June 30, 2013, on Monday, August 5, 2013, after the markets close. Cardica's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on the company's business.

Conference Call Details

To access the live conference call on August 5, 2013, at 4:30 p.m. Eastern Time via phone, please dial 866-515-2912 from the United States and Canada or 617-399-5126 internationally. The conference ID is 98195935. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately two hours after the call through August 12, 2013, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 33703897.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at, a password-protected event management site.

About Cardica 

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 45,200 units throughout the world. In addition, Cardica is developing the Cardica® MicroCutter XCHANGE™ 30, a cartridge-based microcutter device with a five-millimeter shaft diameter, and the Cardica® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device with an eight-millimeter shaft. Both MicroCutter devices are designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 30 and XCHANGE 45 products require 510(k) review and are not yet commercially available in the U.S.


SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting And Stapling Device
2. Cardica Announces Fiscal 2013 Third Quarter Financial Results
3. Cardica to Announce Fiscal 2013 Third Quarter Financial Results On Tuesday, April 30, 2013
4. Cardica Prices Public Offering Of Common Stock
5. Cardica Announces Proposed Public Offering of Common Stock
6. Cardica Updates Enrollment Progress In European Clinical Trial
7. Cardica Announces Fiscal 2013 Second Quarter Financial Results
8. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
9. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
10. Cardica Announces Fiscal 2013 First Quarter Financial Results
11. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
Post Your Comments:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):